Deepa's Recent Publications and
Select Congress Presentations
2011 - today
§ Lubeck DP, Danese MD, Duryea J, Halperin M, Tayama D, Yu E, Lalla D, Grotta JC. Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011. Int J Stroke. 2016 Feb
§ Danese MD, Masaquel A, Santos E, Brammer M, Lee A, Lalla D. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Value Health. 2015 Sep
§ Danese MD, Masaquel A, Santos E, Brammer M, Lee A, Lalla D. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Value Health. 2015
§ Garrison LP Jr, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value Health. 2015
§ Mayer M, Lang K, Hurvitz S, Lalla D, Federico V, Brammer M, Menzin J, Tripathy D. Symptom burden and quality of life among women with HER2(+) metastatic breast cancer. Breast J. 2015
§ Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014 Oct
§ Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014 Jun 13.
§ Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG. Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. Springerplus. 2014 May 8;3:236.
§ Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014 May 21;3:259.
§ Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, Teitelbaum A. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab. J Manag Care Pharm. 2014 May;20(5):485-93.
§ Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS. Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden. Breast Cancer Res Treat. 2014 Apr;144(3):673-81
§ Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. (ePub) Cancer. 2013 Nov 12.
§ Hurvitz SA, Lalla D, Crosby RD, Mathias SD Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res Treat. 2013 Nov 12.
§ Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013;18(7):812-8.
§ Garrison LP Jr, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status Cancer. 2013 Sep 1;119(17):3113-22
§ Anthony Masaquel, Ryan N. Hansen, Scott David Ramsey, Deepa Lalla, Melissa Brammer, Sara A. Hurvitz, Sean D. Sullivan. The cost of adverse events in metastatic breast cancer in taxane- and capecitabine-based regimens. Poster Presentation at ASCO Quality Care Symposium 2013. J Clin Oncol 31, 2013 (suppl 31; abstr 261)
§ Mark Danese, Deepa Lalla, Melissa Brammer, Eduardo Santos, Abraham Lee, Anthony Masaquel. Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013. Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 625)
§ Melissa Brammer, Deepa Lalla, Geneviève Gauthier, Annie Guérin, Philippe Giguere-Duval, Eric Q. Wu, Eduardo Santos. Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting. Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 642)
§ Deepa Lalla, Melissa Brammer, Annie Guérin, Geneviève Gauthier, Philippe Giguere-Duval, Eric Q. Wu, Eduardo Santos. Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab. J Clin Oncol 31, 2013 (suppl; abstr e11603)
§ Ryan N Hansen, Melissa G. Brammer, Scott David Ramsey, Deepa Lalla, Sara A. Hurvitz, Sean D Sullivan. The cost of treatment-related adverse events in metastatic breast cancer therapy: Taxanes versus capecitabine. J Clin Oncol 31, 2013 (suppl; abstr e17527)
§ Louis Garrison, Joseph Babigumira, Anthony Masaquel, Bruce Wang, Deepa Lalla, Melissa Brammer. The lifetime economic burden of inaccurate HER2 testing: Comparing false positive and false negative HER2+ early breast cancer patients in the United States. Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 6626)
§ Mark S. Walker, Anthony Masaquel, Jiandong Kerr, Deepa Lalla, Oyewale O. Abidoye, Obiageli Uchenna Ogbata, Lee Steven Schwartzberg Real-world symptom burden and early treatment discontinuation in first-line metastatic breast cancer (MBC) Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 9619)
§ Impacts of toxicity on patient treatment choices for metastatic breast cancer. White CB, Smith ML, Abidoye O, Lalla D. Poster presentation at American Society of Clinical Oncology - Quality Care Symposium (2012)
§ Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; a retrospective analysis. Gauthier G, Guerin A, Styles A, Q E, Wu EQ, Masaquel A, Brammer MG, Lalla D. Poster presentation at San Antonio Breast Cancer Symposium (2012)
§ Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting. White CB, Smith ML, Abidoye O, Lalla D. Poster presentation at San Antonio Breast Cancer Symposium - (2012)
§ A conjoint analysis of willingness to pay to avoid metastatic breast cancer side effects. Lalla D, Brammer M, Carlton R, Bramley T, D'Souza A. Poster presentation at International Society for Pharmacoeconomics and Outcomes Research: European Congress (2012)
§ Patient-reported outcomes from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs. capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. Welslau M, Dieras V, Sohn J H, Hurvitz SA, Lalla D, Fang L, Guardino E, Miles D. Poster presentation at the European Society for Medical Oncology 37th Congress (2012)
§ Treatment patterns and outcomes in metastatic gastric cancer in the community oncology setting. Walker MS, Lalla D, Houts AC, Schwartzberg LS. Poster presentation at the World Congress on Gastrointestinal Cancer (2012)
§ Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer. Mitchell SA, Lang K, Nichols C, Clauser SB, Federico V, Lalla D, Tripathy D, Hurvitz SA, Castro KM, Reeve BB, Rogak LJ, Denicoff A, Chen A, Piekarz R, Bennett A, Atkinson TM, O’Mara AM, Minasian LM, Basch EM. Poster presentation at American Society of Clinical Oncology (2012)
§ Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou Z Y, Kaminsky MS, Wu EQ, Lalla D. Poster presentation at the American Society of Clinical Oncology (2012)
§ Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. Danese M, Lindquist K, Doan J, Lalla D, Brammer M, Griffiths RI. Journal of Cancer Epidemiology (March 2012)
§ HER2-positive metastatic breast cancer patient experiences on treatment in the biologic era: findings from a community web-based survey. Mayer M, Doan J, Lang K, Hurvitz S, Lalla D, Woodward R, Brammer M, Menzin J, Tripathy D. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ A comparative effectiveness analysis of trastuzumab persistence between two adjuvant breast cancer treatment regimens among U.S. health plan enrollees. Lalla D, Pelletier EM, Goodman S, Brammer M, Schabert VF. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Discordance between central and local laboratory HER2 testing from a large HER2-negative population in VIRGO, a metastatic breast cancer registry. Vogel CL, Bloom K, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Feng S, Brammer MG, Kaufman PA. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Patient-reported outcomes from a randomized phase II study (TDM4450g/BO21976) of trastuzumab emtansine vs trastuzumab plus docetaxel in previously untreated human epidermal growth factor receptor 2-positive metastatic breast cancer. Bianchi GV, Kocsis J, Dirix L, Torigoe Y, Lalla D, Ng V, Guardino AE, Hurvitz SA. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Patient valuation of reduced risk of side effects during treatment for metastatic breast cancer. Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton R. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD. Cancer investigation (September 2011)
§ Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a U.S. based real world population. Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S. Oral Presentation at the European Society for Medical Oncology 36th Congress (2011)
§ Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen. Sail K, Lalla D, Brammer M, Halm M, Patt D. Poster Presentation at the Annual Meeting for the American Society for Clinical Oncology (2011)
§ Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH negative early stage breast cancer patients for HER2 status. Garrison LP Jr, Lalla D, Brammer M, Wang B, Babigumira J, Perez EA. Poster presentation at the Annual Meeting for the American Society for Clinical Oncology (2011). Manuscript submitted to Cancer.
Selected Posters and Publications before 2011 (Complete list available upon request)
§ Estimating recurrences prevented from using trastuzumab in HER-2/neu–positive adjuvant breast cancer in the United States. Danese MD, Knopf K, Brammer M, Lalla D, Doan Q. Cancer (2010).
§ Impact of CNS metastases on treatment and survival in elderly patients receiving trastuzumab for metastatic breast cancer (MBC). Danese MD, Brammer M, Griffiths RI, Doan JF, Lalla D, Lindquist K. Poster presentation at the Annual Meeting for the American Society for Clinical Oncology (2010).
§ First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. Forsyth MT, Chen C, Lalla D, Doan JF, Gruschkus SK, Shing M. Poster presentation at the Annual Meeting for the American Society for Clinical Oncology (2010).
§ Her2 Status and Trastuzumab use among patients with early breast cancer receiving care within the US Oncology Network. Brammer M, Gruschkus S, Lalla D, Doan J, Forsyth M. Poster presentation at the European Society for Medical Oncology. (2010). Winner Best Poster Award
§ Clinical and economic burden of psoriasis. Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Manag Care Interface. 19(4):20-6. (2006)
§ Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Lancet. 7;367(9504):29-35 (2006)
§ Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Br J Dermatol;153(6):1192-9 (2005)
§ Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. J Am Acad Dermatol.;53(5):887-9. (2005)
§ Etanercept Improves Symptoms of Depression and Fatigue in Patients with Moderate to Severe Psoriasis. Krishnan R, Cella D, Woolley JM, Lalla D, Zitnik R, Brajac D. Poster presentation at the Annual Meeting of the American Psychiatric Association (2005)
§ The impact of ITP on Health Related Quality of Life. Lalla D. Podium presentation at the Annual Meeting of the Platelet Disorder Support Association. By Invitation (2004)
§ Initial Results from an Instrument Developed to Evaluate Health Related Quality of Life(HRQOL) in patients with Immune Thrombocytopenic Purpura (ITP). Bussel J, George J, McMillan R, Erder ME, Nichol J, Lalla D. Poster Presentation at the Annual Meeting of the American Society of Hematology (2003)
§ Identifying Initial Diagnosis in Database Research. Lalla DV, Kozma CM. Podium presentation at the International Society for Pharmaceutical Outcomes Research, European Conference (1998)
§ An Economic Model for a Novel Viral Influenza Diagnostic. Kozma CM, Reeder CE, Seeney CE, Livingston PG, Lalla D. Managed Care Interface March 1998:86-93 (1998)
§ Regression toward the Mean: Implications for evaluations of Health Care Interventions. Lalla DV, Kozma CM Podium Presentation at the 145th American Pharmaceutical Association Annual Meeting (1998)
§ Treatment Patterns After Initial Diagnosis of Attention Deficit /Hyperactivity Disorder in the South Carolina Medicaid Population. Lalla DV, McLaughlin TM, Burch SB, Jones GJ, Schulz RS Poster Presentation at the 13th International Conference on Pharmacoepidemiology (1997)
§ Factors Influencing Consumer Choice of Aleve over other OTC Analgesics. Lalla DV, Siganga W, Lively BT, Black C Poster Presentation at the 144th American Pharmaceutical Association Annual meeting (1997)
Select Congress Presentations
2011 - today
§ Lubeck DP, Danese MD, Duryea J, Halperin M, Tayama D, Yu E, Lalla D, Grotta JC. Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011. Int J Stroke. 2016 Feb
§ Danese MD, Masaquel A, Santos E, Brammer M, Lee A, Lalla D. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Value Health. 2015 Sep
§ Danese MD, Masaquel A, Santos E, Brammer M, Lee A, Lalla D. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Value Health. 2015
§ Garrison LP Jr, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value Health. 2015
§ Mayer M, Lang K, Hurvitz S, Lalla D, Federico V, Brammer M, Menzin J, Tripathy D. Symptom burden and quality of life among women with HER2(+) metastatic breast cancer. Breast J. 2015
§ Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014 Oct
§ Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014 Jun 13.
§ Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG. Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. Springerplus. 2014 May 8;3:236.
§ Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014 May 21;3:259.
§ Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, Teitelbaum A. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab. J Manag Care Pharm. 2014 May;20(5):485-93.
§ Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS. Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden. Breast Cancer Res Treat. 2014 Apr;144(3):673-81
§ Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. (ePub) Cancer. 2013 Nov 12.
§ Hurvitz SA, Lalla D, Crosby RD, Mathias SD Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res Treat. 2013 Nov 12.
§ Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013;18(7):812-8.
§ Garrison LP Jr, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status Cancer. 2013 Sep 1;119(17):3113-22
§ Anthony Masaquel, Ryan N. Hansen, Scott David Ramsey, Deepa Lalla, Melissa Brammer, Sara A. Hurvitz, Sean D. Sullivan. The cost of adverse events in metastatic breast cancer in taxane- and capecitabine-based regimens. Poster Presentation at ASCO Quality Care Symposium 2013. J Clin Oncol 31, 2013 (suppl 31; abstr 261)
§ Mark Danese, Deepa Lalla, Melissa Brammer, Eduardo Santos, Abraham Lee, Anthony Masaquel. Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013. Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 625)
§ Melissa Brammer, Deepa Lalla, Geneviève Gauthier, Annie Guérin, Philippe Giguere-Duval, Eric Q. Wu, Eduardo Santos. Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting. Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 642)
§ Deepa Lalla, Melissa Brammer, Annie Guérin, Geneviève Gauthier, Philippe Giguere-Duval, Eric Q. Wu, Eduardo Santos. Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab. J Clin Oncol 31, 2013 (suppl; abstr e11603)
§ Ryan N Hansen, Melissa G. Brammer, Scott David Ramsey, Deepa Lalla, Sara A. Hurvitz, Sean D Sullivan. The cost of treatment-related adverse events in metastatic breast cancer therapy: Taxanes versus capecitabine. J Clin Oncol 31, 2013 (suppl; abstr e17527)
§ Louis Garrison, Joseph Babigumira, Anthony Masaquel, Bruce Wang, Deepa Lalla, Melissa Brammer. The lifetime economic burden of inaccurate HER2 testing: Comparing false positive and false negative HER2+ early breast cancer patients in the United States. Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 6626)
§ Mark S. Walker, Anthony Masaquel, Jiandong Kerr, Deepa Lalla, Oyewale O. Abidoye, Obiageli Uchenna Ogbata, Lee Steven Schwartzberg Real-world symptom burden and early treatment discontinuation in first-line metastatic breast cancer (MBC) Poster Presentation at ASCO 2013. J Clin Oncol 31, 2013 (suppl; abstr 9619)
§ Impacts of toxicity on patient treatment choices for metastatic breast cancer. White CB, Smith ML, Abidoye O, Lalla D. Poster presentation at American Society of Clinical Oncology - Quality Care Symposium (2012)
§ Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; a retrospective analysis. Gauthier G, Guerin A, Styles A, Q E, Wu EQ, Masaquel A, Brammer MG, Lalla D. Poster presentation at San Antonio Breast Cancer Symposium (2012)
§ Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting. White CB, Smith ML, Abidoye O, Lalla D. Poster presentation at San Antonio Breast Cancer Symposium - (2012)
§ A conjoint analysis of willingness to pay to avoid metastatic breast cancer side effects. Lalla D, Brammer M, Carlton R, Bramley T, D'Souza A. Poster presentation at International Society for Pharmacoeconomics and Outcomes Research: European Congress (2012)
§ Patient-reported outcomes from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs. capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. Welslau M, Dieras V, Sohn J H, Hurvitz SA, Lalla D, Fang L, Guardino E, Miles D. Poster presentation at the European Society for Medical Oncology 37th Congress (2012)
§ Treatment patterns and outcomes in metastatic gastric cancer in the community oncology setting. Walker MS, Lalla D, Houts AC, Schwartzberg LS. Poster presentation at the World Congress on Gastrointestinal Cancer (2012)
§ Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer. Mitchell SA, Lang K, Nichols C, Clauser SB, Federico V, Lalla D, Tripathy D, Hurvitz SA, Castro KM, Reeve BB, Rogak LJ, Denicoff A, Chen A, Piekarz R, Bennett A, Atkinson TM, O’Mara AM, Minasian LM, Basch EM. Poster presentation at American Society of Clinical Oncology (2012)
§ Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou Z Y, Kaminsky MS, Wu EQ, Lalla D. Poster presentation at the American Society of Clinical Oncology (2012)
§ Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. Danese M, Lindquist K, Doan J, Lalla D, Brammer M, Griffiths RI. Journal of Cancer Epidemiology (March 2012)
§ HER2-positive metastatic breast cancer patient experiences on treatment in the biologic era: findings from a community web-based survey. Mayer M, Doan J, Lang K, Hurvitz S, Lalla D, Woodward R, Brammer M, Menzin J, Tripathy D. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ A comparative effectiveness analysis of trastuzumab persistence between two adjuvant breast cancer treatment regimens among U.S. health plan enrollees. Lalla D, Pelletier EM, Goodman S, Brammer M, Schabert VF. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Discordance between central and local laboratory HER2 testing from a large HER2-negative population in VIRGO, a metastatic breast cancer registry. Vogel CL, Bloom K, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Feng S, Brammer MG, Kaufman PA. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Patient-reported outcomes from a randomized phase II study (TDM4450g/BO21976) of trastuzumab emtansine vs trastuzumab plus docetaxel in previously untreated human epidermal growth factor receptor 2-positive metastatic breast cancer. Bianchi GV, Kocsis J, Dirix L, Torigoe Y, Lalla D, Ng V, Guardino AE, Hurvitz SA. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Patient valuation of reduced risk of side effects during treatment for metastatic breast cancer. Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton R. Poster presentation at the San Antonio Breast Cancer Symposium (2011)
§ Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD. Cancer investigation (September 2011)
§ Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a U.S. based real world population. Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S. Oral Presentation at the European Society for Medical Oncology 36th Congress (2011)
§ Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen. Sail K, Lalla D, Brammer M, Halm M, Patt D. Poster Presentation at the Annual Meeting for the American Society for Clinical Oncology (2011)
§ Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH negative early stage breast cancer patients for HER2 status. Garrison LP Jr, Lalla D, Brammer M, Wang B, Babigumira J, Perez EA. Poster presentation at the Annual Meeting for the American Society for Clinical Oncology (2011). Manuscript submitted to Cancer.
Selected Posters and Publications before 2011 (Complete list available upon request)
§ Estimating recurrences prevented from using trastuzumab in HER-2/neu–positive adjuvant breast cancer in the United States. Danese MD, Knopf K, Brammer M, Lalla D, Doan Q. Cancer (2010).
§ Impact of CNS metastases on treatment and survival in elderly patients receiving trastuzumab for metastatic breast cancer (MBC). Danese MD, Brammer M, Griffiths RI, Doan JF, Lalla D, Lindquist K. Poster presentation at the Annual Meeting for the American Society for Clinical Oncology (2010).
§ First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. Forsyth MT, Chen C, Lalla D, Doan JF, Gruschkus SK, Shing M. Poster presentation at the Annual Meeting for the American Society for Clinical Oncology (2010).
§ Her2 Status and Trastuzumab use among patients with early breast cancer receiving care within the US Oncology Network. Brammer M, Gruschkus S, Lalla D, Doan J, Forsyth M. Poster presentation at the European Society for Medical Oncology. (2010). Winner Best Poster Award
§ Clinical and economic burden of psoriasis. Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Manag Care Interface. 19(4):20-6. (2006)
§ Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Lancet. 7;367(9504):29-35 (2006)
§ Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Br J Dermatol;153(6):1192-9 (2005)
§ Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. J Am Acad Dermatol.;53(5):887-9. (2005)
§ Etanercept Improves Symptoms of Depression and Fatigue in Patients with Moderate to Severe Psoriasis. Krishnan R, Cella D, Woolley JM, Lalla D, Zitnik R, Brajac D. Poster presentation at the Annual Meeting of the American Psychiatric Association (2005)
§ The impact of ITP on Health Related Quality of Life. Lalla D. Podium presentation at the Annual Meeting of the Platelet Disorder Support Association. By Invitation (2004)
§ Initial Results from an Instrument Developed to Evaluate Health Related Quality of Life(HRQOL) in patients with Immune Thrombocytopenic Purpura (ITP). Bussel J, George J, McMillan R, Erder ME, Nichol J, Lalla D. Poster Presentation at the Annual Meeting of the American Society of Hematology (2003)
§ Identifying Initial Diagnosis in Database Research. Lalla DV, Kozma CM. Podium presentation at the International Society for Pharmaceutical Outcomes Research, European Conference (1998)
§ An Economic Model for a Novel Viral Influenza Diagnostic. Kozma CM, Reeder CE, Seeney CE, Livingston PG, Lalla D. Managed Care Interface March 1998:86-93 (1998)
§ Regression toward the Mean: Implications for evaluations of Health Care Interventions. Lalla DV, Kozma CM Podium Presentation at the 145th American Pharmaceutical Association Annual Meeting (1998)
§ Treatment Patterns After Initial Diagnosis of Attention Deficit /Hyperactivity Disorder in the South Carolina Medicaid Population. Lalla DV, McLaughlin TM, Burch SB, Jones GJ, Schulz RS Poster Presentation at the 13th International Conference on Pharmacoepidemiology (1997)
§ Factors Influencing Consumer Choice of Aleve over other OTC Analgesics. Lalla DV, Siganga W, Lively BT, Black C Poster Presentation at the 144th American Pharmaceutical Association Annual meeting (1997)